LGLSLouis Goldberg Library Suppliers (Nazareth, PA)
References in periodicals archive ?
Meantime, Kyorin will receive up-front and milestone payments, as well as royalties from LGLS.
LB03002 was originally developed by LGLS who granted Biopartners a license to further develop and market the product in Europe, Australia, New-Zealand and several other countries.
BioHydrix[R] is an LGLS proprietary sustained release (SR) technology with significant potential in the delivery of biologics.
LGLS is committed to developing a leading portfolio of drugs that prevent, treat and cure diseases across a broad range of therapeutic areas and delivering values and quality medicines to patients.
com or call the LGLS Investor Relations Team at 82-2-3773-1114.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of LGLS and/or Anadys Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements.
Outside North America and Europe, LGLS will market the drug under the global brand FACTIVE.